DK0559413T3 - - Google Patents
Info
- Publication number
- DK0559413T3 DK0559413T3 DK93301534.9T DK93301534T DK0559413T3 DK 0559413 T3 DK0559413 T3 DK 0559413T3 DK 93301534 T DK93301534 T DK 93301534T DK 0559413 T3 DK0559413 T3 DK 0559413T3
- Authority
- DK
- Denmark
- Prior art keywords
- meta
- treatment
- neurodegenerative diseases
- nicotine compound
- nicotine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/844,364 US5212188A (en) | 1992-03-02 | 1992-03-02 | Method for treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0559413T3 true DK0559413T3 (es) | 1997-03-10 |
Family
ID=25292523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93301534.9T DK0559413T3 (es) | 1992-03-02 | 1993-03-01 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5212188A (es) |
EP (1) | EP0559413B1 (es) |
JP (1) | JPH0624983A (es) |
AT (1) | ATE143263T1 (es) |
DE (1) | DE69304955T2 (es) |
DK (1) | DK0559413T3 (es) |
ES (1) | ES2093361T3 (es) |
GR (1) | GR3022072T3 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
DE69535131T2 (de) * | 1995-01-06 | 2007-03-01 | Targacept, Inc. | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems |
US5824692A (en) * | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5731314A (en) * | 1995-01-06 | 1998-03-24 | Bencherif; Merouane | Pharamceutical compositions for prevention and treatment of tourette's syndrome |
US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US20020052497A1 (en) * | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
US6166048A (en) | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
EP0900200B9 (en) | 1996-04-23 | 2009-10-21 | Targacept, Inc. | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
US5811442A (en) * | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
US6531606B1 (en) * | 1997-02-21 | 2003-03-11 | Targacept, Inc. | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
US7214686B2 (en) * | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
EP1056458B1 (en) * | 1998-02-24 | 2005-04-27 | Wake Forest University | Treatment of chronic pain |
AU2880699A (en) | 1998-04-02 | 1999-10-25 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions and methods for use |
US20050131034A1 (en) * | 1998-06-16 | 2005-06-16 | Caldwell William S. | Compounds capable of activating cholinergic receptors |
US7790757B2 (en) * | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
US6262124B1 (en) * | 1998-10-22 | 2001-07-17 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
US6455554B1 (en) | 1999-06-07 | 2002-09-24 | Targacept, Inc. | Oxopyridinyl pharmaceutical compositions and methods for use |
JP2003501416A (ja) * | 1999-06-07 | 2003-01-14 | ターガセプト,インコーポレイテッド | 医薬組成物およびその使用法 |
US6890935B2 (en) * | 1999-11-01 | 2005-05-10 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
FR2810886B1 (fr) * | 2000-06-05 | 2002-12-27 | Sanjuan Benito Arranz | Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux) |
US6852741B2 (en) * | 2001-12-31 | 2005-02-08 | University Of Florida | Compositions and methods for treatment of neurological disorders |
US7074812B2 (en) * | 2002-08-02 | 2006-07-11 | Nutraleutical Development Corporation | Development of muscle mass in a mammal |
EP1678172B1 (en) * | 2003-10-15 | 2009-12-09 | Targacept, Inc. | Azabicyclic compounds for relieving pain and treating central nervous system disorders |
AU2004318159B8 (en) * | 2004-04-02 | 2011-05-26 | Sahajanand Medical Technologies Private Limited | Polymer-based stent assembly |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
US8017785B2 (en) * | 2006-05-09 | 2011-09-13 | Astrazeneca Ab | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine |
TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
AR062860A1 (es) * | 2006-09-15 | 2008-12-10 | Astrazeneca Ab | Combinaciones terapeuticas 482 |
EP2112923A1 (en) * | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
US7718677B2 (en) * | 2007-04-02 | 2010-05-18 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
JP2010535237A (ja) * | 2007-07-31 | 2010-11-18 | ターガセプト・インコーポレイテッド | (2s)−(4e)−n−メチル−5−(3−(5−イソプロポキシピリジン)イル)−4−ペンテン−2−アミンの経皮投与 |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
KR20130081221A (ko) | 2010-05-20 | 2013-07-16 | 아스트라제네카 아베 | 아릴 치환된 올레핀계 아민의 신규 제조 방법 |
EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE |
CA2949395C (en) * | 2014-05-16 | 2024-01-02 | Synaptec Development Llc | Clearance of amyloid.beta. |
JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 薬剤送達方法及びシステム |
EP3267875A4 (en) | 2015-03-12 | 2018-12-05 | Chrono Therapeutics Inc. | Craving input and support system |
US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
JP2020503950A (ja) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 経皮薬剤送達の装置及び方法 |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870794A (en) * | 1974-02-20 | 1975-03-11 | Foundation For Behavioral Rese | Treatment of certain emotional disorders with nicotine compounds |
HU179164B (en) * | 1979-12-14 | 1982-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing cycloalkyl-ethers of alkanolamines |
US4442292A (en) * | 1981-01-29 | 1984-04-10 | Philip Morris Incorporated | Optically active nicotine analogs and process for their preparation |
US4578394A (en) * | 1984-12-10 | 1986-03-25 | Hoechst-Roussel Pharmaceuticals Incorporated | Cholinergic function increasing 3-[N-(pyridyl) carbamoyl]-1,4-dihydropyridines |
US4965074A (en) * | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
US4765985A (en) * | 1985-03-05 | 1988-08-23 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
US4863930A (en) * | 1986-12-19 | 1989-09-05 | Adhikary Parimal K | Use of substituted 5H-pyrido- and 5H-thiazolo(2',1':2,3)imidazo (4,5-b)indoles as cholinomimetic agents |
IL88156A (en) * | 1987-11-13 | 1997-02-18 | Novo Nordisk As | Azacyclic compounds their preparation and pharmaceutical compositions containing them |
IE62662B1 (en) * | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
US5015741A (en) * | 1989-10-03 | 1991-05-14 | Philip Morris Incorporated | Nicotine analogs |
-
1992
- 1992-03-02 US US07/844,364 patent/US5212188A/en not_active Expired - Lifetime
-
1993
- 1993-03-01 EP EP93301534A patent/EP0559413B1/en not_active Expired - Lifetime
- 1993-03-01 DK DK93301534.9T patent/DK0559413T3/da active
- 1993-03-01 AT AT93301534T patent/ATE143263T1/de not_active IP Right Cessation
- 1993-03-01 JP JP5062489A patent/JPH0624983A/ja not_active Withdrawn
- 1993-03-01 DE DE69304955T patent/DE69304955T2/de not_active Expired - Fee Related
- 1993-03-01 ES ES93301534T patent/ES2093361T3/es not_active Expired - Lifetime
-
1996
- 1996-12-18 GR GR960403517T patent/GR3022072T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
GR3022072T3 (en) | 1997-03-31 |
US5212188A (en) | 1993-05-18 |
EP0559413A1 (en) | 1993-09-08 |
EP0559413B1 (en) | 1996-09-25 |
ES2093361T3 (es) | 1996-12-16 |
DE69304955T2 (de) | 1997-04-10 |
ATE143263T1 (de) | 1996-10-15 |
JPH0624983A (ja) | 1994-02-01 |
DE69304955D1 (de) | 1996-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0559413T3 (es) | ||
TW249226B (es) | ||
HU9300536D0 (en) | Compounds of medical effect | |
EP0455448A3 (en) | Treatment of pancreatic disease with 15-keto-prostaglandin compounds | |
EP0467564A3 (en) | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | |
AP9200428A0 (en) | Compounds for treating leukotriene-related diseases | |
EP0545511A3 (en) | Process for the preparation of mono-n-substituted tetraazamacrocycles | |
AU2806692A (en) | Medicament for the treatment of anxiety | |
AU1450392A (en) | Small peptidic compounds useful for the treatment of glaucoma | |
ZA886247B (en) | Use of a compound for the treatment of schizophrenia | |
ZA931063B (en) | Treatment of glaucoma. | |
AU4081393A (en) | Medicaments for the treatment of anxiety | |
AU639322B2 (en) | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds | |
GR3022217T3 (en) | Treatment of cataract with prostacyclin compounds | |
AU5654994A (en) | Use of dinaphthalenes compounds as antiproliferative agents | |
AU5018893A (en) | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases | |
IL106064A (en) | Gallium complexes for the treatment of free radical-induced diseases | |
NZ255753A (en) | Use of substituted azaspiranes for psoriasis treatment | |
AU5532094A (en) | Therapeutic agents for the treatment of cachexia | |
ZA925258B (en) | Unit for the treatment of effluent | |
AU1455992A (en) | Organosulphur compounds useful for the treatment of glaucoma | |
GB9222934D0 (en) | Therapeutic compounds | |
GB9226526D0 (en) | Therapeutic compounds | |
GB9218223D0 (en) | The use of a compound for the manufacture of a medicament for the treatment of hiv infection | |
GB9201764D0 (en) | The use of a compound for the manufacture of a medicament for the treatment of hiv infection |